Communiqué pour la presse professionnelle

GEA to highlight the benefits of partnership during vaccine plant production at ACHEMA Pulse

24 Mar 2021

GEA, one of the world's leading companies in mechanical and plant engineering, will participate in the upcoming virtual ACHEMA Pulse (15–16 June) and address some of the key issues facing today’s manufacturers of biopharmaceuticals.

GEA is committed to “Engineering for a better world,” designing and building modular plants and fully integrated systems that meet the extremely high demands of today’s biotechnology and pharmaceutical industries. (Courtesy: Damian Poffet)

GEA is committed to “Engineering for a better world,” designing and building modular plants and fully integrated systems that meet the extremely high demands of today’s biotechnology and pharmaceutical industries. (Courtesy: Damian Poffet)

Despite the incredible achievements that have been made in terms of developing and delivering a number of approved and administered Covid-19 vaccines in recent times, governments, politicians and the general public alike are still questioning why it takes 3-5 years to bring a commercial-scale biopharmaceutical manufacturing plant to full operational functionality.

Furthermore, they want to know what can be done about it. GEA Group’s Heinrich Meintrup, Head of Pharma & Healthcare, believes that the key to significantly shortening this timeframe is modularization, digitalization and collaboration. In his presentation, “How Can We Fast-Track Vaccine Plant Production and Ensure Safety of Outcome?” he will explain how, based on a foundation of trust and existing know-how, working with a partnership approach can reduce the complexity, cost and risk of successful drug production.

By subscribing to a philosophy of standardization and modularization, a digitally enhanced project delivery process and keeping the number of interfaces to a minimum, significant gains can be made.

“We have to make the best use of existing intelligent solutions,” advises Meintrup, “adhere to current standards and regulations, and focus on mutually agreed targets and incentives. Disruptions and delays can cost millions of dollars; but, by taking a smarter and leaner approach, GEA believes that the design, construction and qualification of pharmaceutical manufacturing plant and facilities can be accelerated, simplified and delivered with predictable outcomes in a shorter timeframe.”

Contact

Dr. Michael Golek

Phone: 49 211 9136 1505

Media Relations

GEA Group Aktiengesellschaft

Peter-Müller-Str. 12


40468

Düsseldorf


Germany

+49 211 9136-0

À propos de GEA

GEA est un des principaux fournisseurs de l'industrie agroalimentaire et d'autres industries, qui sont à l’origine d’un revenu consolidé qui a atteint près de 4,9 Mrd EUR en 2019.

C’est un groupe international spécialisé dans les machines et les installations, ainsi que dans les technologies de procédés et composants. GEA fournit des solutions énergétiques durables, utilisées dans des process de production de pointe pour divers marchés, et offre une gamme complète de services. Le groupe réalise près de 70 % de son revenu dans l'industrie alimentaire et des boissons, un secteur caractérisé par une croissance durable de long terme. Au 31 décembre 2018, la société employait plus de 18 500 personnes dans le monde. GEA est un leader du marché et des technologies dans ses secteurs d'activité. La société est cotée sur l'indice boursier allemand MDAX (G1A, WKN 660 200), sur l'indice STOXX® Europe 600 et sur des indices de durabilité globale MSCI sélectionnés.
Recevez l’actualité de GEA

Restez au courant des innovations et des activités de GEA en vous inscrivant aux actualités de GEA.

Contactez-nous

Nous sommes là pour vous aider ! Nous avons besoin de quelques renseignements pour pouvoir répondre à votre demande.